COVID-19: ACIP & CDC recommends that persons ≥ 65 years of age should receive an additional dose of 2023-2024 Formula COVID-19 vaccine at least four months after previous updated (2023-2024) COVID-19 vaccine dose.

Children 3 years and older can now receive any CDC recommended vaccination without a prescription at Grubb's Pharmacy. Children under the age of 3 years still requires a prescription.  

RSV Vaccine (Abrysvo) for use in pregnant women between 32 through 36 weeks gestation is still available at Grubb's but a prescription is needed during non-RSV season (Feb - Aug). 

PAXLOVID for the treatment of mild-moderate COVID-19 disease is available at Grubb's Pharmacy. Paxlovid is now a commercial product and will be covered under your prescription benefits with a possible copay.  Copay assistance may be available through the Paxlovid copay savings program.

Grubb's Pharmacy is a provider in The Bridge Access Program which provides individuals who are 18 years and older and without insurance a way to receive free COVID-19 vaccinations. Visit www.CovidAccess.com and search Grubb's by using our zip code 20003.  

Individuals 5 years of age and older regardless of previous vaccination are eligible to receive a single dose of an updated mRNA COVID-19 vaccine at least 2 months since the last dose of any COVID-19 vaccine. 

Individuals 6 months through 4 years of age who have previously been vaccinated against COVID-19 are eligible to receive one or two doses of an updated mRNA COVID-19 vaccine (timing and number of doses to administer depends on the previous COVID-19 vaccine received). 

Unvaccinated individuals 6 months through 4 years of age are eligible to receive three doses of the updated authorized Pfizer-BioNTech COVID-19 Vaccine or two doses of the updated authorized Moderna COVID-19 Vaccine. 

RSV (Respiratory Syncytial Virus) Vaccine is now available at Gubb's. There are two vaccines available:  Arexvy and Abrysvo are both approved for use in adults over the age of 60 to reduce their risk of developing lower respiratory tract disease (LRTD). Abrysvo is also approved for use in pregnant women between 32 through 36 weeks gestation, to protect infants against LRTD from the moment they are born until they are 6 months of age, making it the first RSV vaccine to be FDA-approved for this purpose.